Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals launched a U.S. Expanded Access Program for up to 250 adults with post-bariatric hypoglycemia to provide access to its investigational therapy avexitide. The first-in-class GLP-1 receptor antagonist is currently being evaluated in the pivotal Phase 3 LUCIDITY trial, with topline data anticipated in Q3 2026 and a potential commercial launch in 2027.
Key figures
- Drug Name
- avexitide
- Phase Of Trial
- Phase 3
- Dosage mg
- 90
- Trial sites
- 21
- Eap capacity
- 250
- Trial participants
- 78
- Topline data timeline
- Q3 2026
- Us prevalence estimate
- 160000
- Commercial launch timeline
- 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.